Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 693 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Atopic Dermatitis Clear all
Terminated Not applicable Interventional

Health Literacy for Children With Atopic Dermatitis and Their Caregivers

NCT01138761
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Nurse instruction
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
Up to 7 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 23, 2026, 3:08 AM EDT
Terminated Phase 3 Interventional

Atopic Dermatitis-Like Skin Disease in Pediatric Heart Transplant Patients

NCT00176956
View directory record Official record
Conditions
Dermatitis
Interventions
Skin Biopsy
Procedure
Lead sponsor
Hordinsky, Maria K., MD
Individual
Eligibility
Up to 16 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Oct 23, 2026, 3:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comprehensive Investigation of Heart Rate Variability as a Measure of the Autonomic Nervous System in Atopic Dermatitis

NCT00691366
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 23, 2026, 3:08 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)

NCT04417894
View directory record Official record
Conditions
Moderate to Severe Atopic Hand and Foot Dermatitis
Interventions
dupilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
17
States / cities
Birmingham, Alabama • Redwood City, California • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 23, 2026, 3:08 AM EDT
Not listed Phase 2 Interventional

Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis

NCT03351777
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PR022
Drug
Lead sponsor
Realm Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Oct 23, 2026, 3:08 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis

NCT03054428
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis, Dermatitis, Dermatitis Atopic, Eczema, Skin Diseases, Skin, Diseases Genetic, Genetic, Diseases Inborn, Skin, Disease, Eczematous Skin, Hypersensitivity, Immediate, Hypersensitivity, Immune System Diseases, Dermatitis, Atopic
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
36
States / cities
Birmingham, Alabama • Gilbert, Arizona • Bakersfield, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 23, 2026, 3:08 AM EDT
Completed Phase 1 Interventional

Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis

NCT01678092
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
omalizumab
Biological
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 25 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2015 · Synced Oct 23, 2026, 3:08 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

NCT04018027
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
difelikefalin 0.25 mg, difelikefalin 0.5 mg, difelikefalin 1.0 mg, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
38
States / cities
Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 23, 2026, 3:08 AM EDT
Completed Not applicable Interventional

Bleach vs. Bubbles: Assessing the Impact of the Bathroom Environment on Eczema

NCT03619161
View directory record Official record
Conditions
Eczema, Atopic Dermatitis, Atopic Dermatitis and Related Conditions
Interventions
Bubbles, Bleach and Bubbles
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
6 Months to 17 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 23, 2026, 3:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate ASN008 Topical Gel (TG)

NCT03798561
View directory record Official record
Conditions
Dermatitis, Atopic, Pruritus, Dermatitis Eczema
Interventions
ASN008 TG, Placebo TG
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
4
States / cities
Cortland, New York • High Point, North Carolina • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 23, 2026, 3:08 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

NCT03720470
View directory record Official record
Conditions
Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases, Skin Diseases, Genetic, Genetic Diseases, Inborn, Skin Diseases, Eczematous, Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases
Interventions
PF-04965842 100 mg, PF-04965842 200 mg, Dupilumab, Oral Placebo, Injectable Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
60
States / cities
Birmingham, Alabama • Huntington Beach, California • Laguna Hills, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 23, 2026, 3:08 AM EDT
Completed Phase 2 Interventional Results available

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis

NCT02871479
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
SAN007 5% cream, Placebo, SAN007 10% cream
Drug
Lead sponsor
Santalis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Austin, Texas • Bryan, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 23, 2026, 3:08 AM EDT
Enrolling by invitation Phase 3 Interventional

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT05735483
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Lebrikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months to 18 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • North Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 23, 2026, 3:08 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring

NCT05721937
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Abrocitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 23, 2026, 3:08 AM EDT
Enrolling by invitation Early Phase 1 Interventional

Thera-Clean® Microbubbles System in Patients With Skin Diseases

NCT07050810
View directory record Official record
Conditions
Epidermolysis Bullosa, Ichthyosis, Atopic Dermatitis, Psoriasis
Interventions
TheraClean
Device
Lead sponsor
Northwestern University
Other
Eligibility
2 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 23, 2026, 3:08 AM EDT
Terminated Phase 2 Interventional Results available

A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis

NCT03809663
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tezepelumab, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
16
States / cities
Fountain Valley, California • Santa Monica, California • Alpharetta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 23, 2026, 3:08 AM EDT
Terminated Phase 4 Interventional

Dupilumab De-escalation in Pediatric Atopic Dermatitis

NCT06116526
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab - Discontinuation, Dupilumab - Dose Reduction, Dupilumab - Standard Dose
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
1 Year to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 23, 2026, 3:08 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients

NCT00121316
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
12 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
0
States / cities
Not listed
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 23, 2026, 3:08 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis

NCT04562116
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Nemolizumab, CYP 450 Substrates
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
North Hollywood, California • Hallandale, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 23, 2026, 3:08 AM EDT
Completed No phase listed Observational

Assessing Risk of Food Insecurity Within Households of Children With Food Allergy

NCT01897506
View directory record Official record
Conditions
Food Allergy, Asthma, Allergic Rhinitis, Atopic Dermatitis, Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
1 Year to 17 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Oct 23, 2026, 3:08 AM EDT
Completed Phase 2 Interventional Results available

Secukinumab for Treatment of Atopic Dermatitis

NCT02594098
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 23, 2026, 3:08 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema

NCT00817063
View directory record Official record
Conditions
Eczema
Interventions
alitretinoin, Placebo
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
70
States / cities
Birmingham, Alabama • Tucson, Arizona • Fort Smith, Arkansas + 64 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Oct 23, 2026, 3:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Skin Barrier Biophysical Properties and Clinical Appearance After Moisturizer in Dry Skin

NCT03093597
View directory record Official record
Conditions
Xerosis, Xerosis Cutis, Dry Skin; Eczema
Interventions
virgin coconut oil, virgin jojoba oil, virgin almond oil, white petrolatum ointment
Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Tucson, Arizona • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 23, 2026, 3:08 AM EDT
Completed Phase 2 Interventional

Efalizumab for Eczema

NCT00146003
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Efalizumab treatment
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 7, 2008 · Synced Oct 23, 2026, 3:08 AM EDT